Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The study of dapagliflozin versus sitagliptin treatment efficacy on preventing cardiovascular risk factors in type 2 DM patients (DIVERSITY-CVR study)

Next Previous
X
Search
Trial Profile

The study of dapagliflozin versus sitagliptin treatment efficacy on preventing cardiovascular risk factors in type 2 DM patients (DIVERSITY-CVR study)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dapagliflozin (Primary) ; Sitagliptin
  • Indications Cardiovascular disorders; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms DIVERSITY-CVR study

    • Most Recent Events

    • 06 Oct 2023 Results of sub-analysis of the DIVERSITY-CVR study assessing Effects of sitagliptin versus dapagliflozin on time in range in Japanese patients with type 2 diabetes stratified by body mass index presented at the 59th Annual Meeting of the European Association for the Study of Diabetes
    • 11 Jun 2019 Primary endpoint (Ratio of achieving a composite endpoint of the following 3 items from baseline to the 24th week 1. HbA1c below 7% 2. Body weight loss of 3% 3. Avoidance of hypoglycemia (Level 2)) has been met as per results presented at the 79th Annual Scientific Sessions of the American Diabetes Association
    • 11 Jun 2019 Results presented at the 79th Annual Scientific Sessions of the American Diabetes Association

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top